5-Fluorouracil (5-FU) plays an important role in the treatment of several tumor types, particularly colorectal cancer and breast cancer. Xeloda® (capecitabine; 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl-cytidine]) is a new rationally designed fluoropyrimidine carbamate. It is administrated orally and after absorption it is first metabolized to 5′-deoxy-5-fluorocytidine (5′-DFCR) by carboxylesterase from the liver and then converted to 5′-deoxy-5-fluorouridine (5′-DFUR) by cytidine deaminase from the liver and tumor tissues. Finally, thymidine phosphorylase (TP) converts 5′-DFUR to 5-FU. TP is more active in tumor tissues than in normal tissue. This tissue localization pattern results in preferential metabolism and generates higher levels of 5-FU in malignant tissue, thus enhancing efficacy but minimizing side effects. The tumor tissue selectivity was confirmed in a study of 19 patients with colorectal cancer. After Xeloda administration, concentrations of 5-FU were 2.5 times higher in the primary tumor compared with adjacent healthy tissue. Xeloda was highly active in human tumor xenografts. It was more active than 5-FU, 5′-DFUR and tegafur plus uracil (UFT) and had a better therapeutic index. Xeloda also demonstrated synergistic or additive activity when used in combination with cyclophosphamide, methotrexate, doxorubicin, paclitaxel and docetaxel. This may be in part a result of up-regulation of TP by the cytotoxic agents. Phase I and II clinical trials have shown that Xeloda is active across a range of tumor types, and phase III studies are ongoing.

Keywords:
Xeloda® (capecitabine), 5-Fluorouracil, Fluoropyrimidines, Solid tumors, Tumor-selective activation, Oral chemotherapy
1.
Miwa M, Ura M, Nihida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishisuka H: Design of an oral fluoropyrimidine carbonate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;1274–1281.
2.
Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998;58/4:685–690
3.
Pinedo HM, Peters GF: Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 1988;6:1653–1664.
4.
Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4/4:1013–1019.
5.
Ishikawa T, Fukase Y, Yamamoto T, Umeda I, Shimma N, Ishitsuka H: Antitumor activity of Ro 09-1978, N4-pentoxyloxycarbonyl-5′-DFCR. Proc Jpn Cancer Assoc (abstr) 1994;2410.
6.
Ishikawa T, Fukase Y, Yamamoto T, Ishitsuka H: Jpn Soc Cancer Ther 1995;30:8.
7.
Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013–1019.
8.
Sawada N, Ishikawa T, Yoshikubo T, Nishida M, Ishitsuka H: Jpn Soc Cancer Ther 1996;31:722.
9.
Ishikawa T, Utoh M, Sawada N, Sekiguchi F, Ishitsuka H: XelodaTM (capecitabine): An orally available tumor-selective fluoropyrimidine carbamate. Proc Am Soc Clin Oncol 1997;16:208a (abstract 727).
10.
Beale P, Aherne W, Judson I, Trigo J, Wolf L, Walker R, Crompton T, Yin H, Mulligan T, Jones D, Reigner BG: Excretion balance and pharmacokinetic study of XelodaTM in cancer patients. Ann Oncol 1998;9 (suppl 2):119.
11.
Reigner BG, Verweij J, Dirix L, Cassidy J, Twelves C, Allman D, Weidekamm E, Roos B, Banken L, Utoh M, Osterwalder B: Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 1998;4:941–948.
12.
Reigner BG, Glynne Jones R, Cassidy J, Schuller J, Goggin T, Jones D, Twelves C: Hepatic dysfunction due to liver metastasis does not affect the bioactivation of XelodaTM. Proc Am Soc Clin Oncol 1998;17:224a (abstract 863).
13.
Schuller J, Cassidy J, Reigner BG, Roos B, Pietrzak C, Springer B, Ishitsuka H, Dumont E: Tumor selective activation of Capecitabine in colorectal cancer patients. Onkologie 1997;20 suppl 1 (abstract 732).
14.
Kovach JS, Beart RW: Cellular pharmacology of fluorinated pyrimidines in vivo in man. Invest New Drugs 1989;7:13–25.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.